ERBB2 and breast cancer: The majority of patients carried luminal BC subtype (13 out of 20, 65%), a Triple Negative BC (TNBC) subtype was reported in 6 out of 20 of patients (30%), while only 1 (5%) patient had a HER2+ tumor.